Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
Pfizer (PFE) and AbbVie (ABBV) are major U.S. drugmakers with diversified portfolios. Pfizer expects flat to slightly negative revenue growth in 2026 but aims for high single-digit CAGR from 2028. AbbVie anticipates 10.5% sales growth in 2026, driven by Skyrizi and Rinvoq. Both companies face patent expirations and competition. Analysts expect Pfizer's 2026 EPS to decrease 7.5%, while AbbVie's is projected to rise 40.5%.
How this was made
The 30-second read
Why it matters
Both companies face distinct growth drivers and challenges; no new data beyond existing guidance.
Market read
Provides a comparative view for investors deciding between two large‑cap pharma stocks.
What to watch
Potential impact of upcoming obesity drug berobenatide pipeline not reflected in current guidance.
Background
The article compares Pfizer and AbbVie based on recent guidance, pipeline expectations, and valuation metrics.
Ticker impact
Pfizer guidance shows flat to slightly negative 2026 growth and a $1.1B revenue hit from upcoming patent expirations.
Potential modest downside or sideways movement pending further guidance.
Guidance is already public and reflects known challenges; no new catalyst.
AbbVie projects >$31B combined sales for Skyrizi and Rinvoq in 2026 with >20% growth, despite pricing headwinds.
Possible modest upside if growth materializes; otherwise limited.
Projections are forward‑looking estimates, not a new earnings release.
Market effects
Highlights divergent growth narratives within the U.S. pharma sector.
U.S. large‑cap pharma investors may re‑balance between dividend yield and growth prospects.
Limited; primarily U.S. market focus.
Counterpoint
Pfizer's high dividend may still attract income‑focused investors despite flat growth.
Key entities
- companyPfizer
U.S. pharmaceutical giant with flat 2026 guidance.
- companyAbbVie
U.S. pharmaceutical firm projecting strong immunology sales growth.
